SUMMARY A 19 year old woman with Ullrich-Noonan syndrome presented with a six month history of progressive dyspnoea and cyanosis. Clinical features were suggestive of severe pulmonary hypertension. Cross sectional echocardiography showed pronounced right ventricular pressure overload with right ventricular hypertrophy. Cardiac catheterisation confirmed severe pulmonary hypertension. Attempts to reduce pulmonary artery pressure with calcium channel blockers were unsuccessful. The patient died shortly after investigation. Necropsy confirmed primary pulmonary hypertension.
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The Ullrich-Noonan syndrome is an autosomal dominant condition of both sexes in which the affected individuals have many of the phenotypic features of Turner's syndrome, but with a normal karyotype and normal secondary sexual characteristics. There is a predisposition to cardiac anomalies, the most commonly described being pulmonary valve stenosis (often associated with an atrial septal defect) and asymmetrical septal hypertrophy." We report a case of severe primary pulmonary hypertension occurring in association with this syndrome and describe the clinical features and pathological findings of a plexogenic arteriopathy.
Case report
A 19 year old woman was admitted to hospital with a six month history of progressive dyspnoea on exertion. Ullrich-Noonan syndrome was diagnosed when she was two years old and since infancy her exercise tolerance had been reduced by dyspnoea. In the six months before presentation she could only walk 200 metres. This limitation was associated with central cyanosis and a tight central chest pain which resolved on resting. There was no history of syncope. She was also profoundly deaf, but of normal intelligence. Both parents were also profoundly deaf, and her father had the Ullrich-Noonan syndrome. She also had a 17 year old sister with the same syndrome, but with normal hearing, in whom pulmonary stenosis was diagnosed at four months. 
Discussion
The commonest cause of pulmonary hypertension in children and young adults is an intracardiac shunt. It has been suggested that pulmonary hypertension occurs in up to 15% of patients with atrial septal defects,5 but is rare before the third decade.67
Primary pulmonary hypertension is a rare disease that usually occurs in young women (aged 15-40). 9 We believe that the severe pulmonary hypertension described in this patient is likely to be of the Severe pulmonary hypertension in Ullrich-Noonan syndrome 77 primary type. The small atrial septal defects seem to be insignificant in view of hypertrophied, but not dilated, right ventricle and normally sized right atrium, which would exclude a previous large pretricuspid shunt.'0 Pulmonary hypertension secondary to atrial septal defects is associated with cardiomegaly (cardiothoracic ratio > 0 6) in both older," and younger patients.7 In this case, the cardiothoracic ratio was < 0 5. There has been only one reported case of the Eisenmenger syndrome in association with an atrial septal defect at this age. 6 Other features supporting primary type hypertension are the rapid clinical deterioration and the very high pulmonary artery pressure and pulmonary vascular resistance. In addition, the presence and widespread distribution of dilated plexiform and angiomatoid lesions suggest a primary defect.""'4
The treatment of severe pulmonary hypertension is unsatisfactory, in the absence of a remediable cause. Because of the unproven hypothesis that vasoconstriction is important in the pathophysiology of primary pulmonary hypertension, vasodilating agents have been used as treatment, with disappointing results.'5 A recent short term improvement, however, was achieved in pulmonary artery haemodynamic function with regression of right ventricular hypertrophy with calcium channel blockers.'6 '7 Though the patient reported here showed partial reversibility of the pulmonary vascular resistance during administration of high flow oxygen (table 2), the calcium channel blockers did not affect pulmonary artery pressure or pulmonary vascular resistance.
The small atrial communication does not seem to be relevant to the pulmonary hypertension. The clinical and pathological features suggest the development of primary pulmonary hypertension in this patient with the Ullrich-Noonan syndrome.
